Fluidigm Corporation Revenue and Competitors
Estimated Revenue & Valuation
- Fluidigm Corporation's estimated annual revenue is currently $136.9M per year.
- Fluidigm Corporation received $30.0M in venture funding in August 2017.
- Fluidigm Corporation's estimated revenue per employee is $252,155
- Fluidigm Corporation's total funding is $375.2M.
- Fluidigm Corporation's current valuation is $239.4M. (January 2022)
Employee Data
- Fluidigm Corporation has 543 Employees.
- Fluidigm Corporation grew their employee count by -1% last year.
Fluidigm Corporation's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP, R+D | Reveal Email/Phone |
2 | SVP, Global Operations | Reveal Email/Phone |
3 | SVP, Regulatory Affairs and Quality Assurance | Reveal Email/Phone |
4 | Senior Director | Reveal Email/Phone |
5 | Senior Director R&D, Engineering | Reveal Email/Phone |
6 | Associate Director, HRBP at Fluidigm Corporation | Reveal Email/Phone |
7 | Director, Mechanical Engineering | Reveal Email/Phone |
8 | Senior Director Product Management | Reveal Email/Phone |
9 | Senior Director, Assay Development | Reveal Email/Phone |
10 | Director Reagents Manufacturing and Operations | Reveal Email/Phone |
Fluidigm Corporation Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Fluidigm Corporation?
Improving life. It's what drives us each day. At Fluidigm, we empower our customers to reveal meaningful insights in health and disease, efficiently identify actionable markers to inform life decisions and accelerate the development of more effective therapies. We focus on the most pressing needs in translational and clinical research, including cancer, immunology and immunotherapy. Harnessing proprietary CyTOF® and microfluidics capabilities, we provide an unprecedented view into health and disease through our unique combination of innovative mass cytometry, tissue imaging and genomics solutions. Researchers depend on our systems to uncover important disease pathways, find valuable new molecular biomarkers and deeply profile important cell populations down to single cell resolution. As a trusted partner of leading academic, government, pharmaceutical, biotechnology and plant and animal research laboratories worldwide, we strive to increase the quality of life for all.
keywords:Biotechnology,Cleantech,Hardware,Healthcare,Medical Devices,Medical Diagnostics,Pharmaceuticals,Solar Power,Wind Power
$375.2M
Total Funding
543
Number of Employees
$136.9M
Revenue (est)
-1%
Employee Growth %
$239.4M
Valuation
N/A
Accelerator
Fluidigm Corporation News
Fluidigm has been renamed Standard BioTools Inc. (Standard BioTools) and its common stock is expected to begin trading on Nasdaq under the...
SOUTH SAN FRANCISCO, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM) today announced that its stockholders...
Fluidigm Board to Appoint Frank Witney, a Director Candidate ... 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM) today announced...
Base business rebounds. Promising early reception to 4th generation mass cytometry instrument. Services business achieves quarterly revenue record of $6.6 million. SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tool ...
Forecasting underlying base business growth of 16–17% supported by new product innovation SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insig ...
Other Companies in San Francisco
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $100M | 543 | 1% | $138.7M |
#2 | $96.7M | 544 | 18% | $146M |
#3 | $143.1M | 545 | 51% | N/A |
#4 | $155.6M | 546 | 6% | N/A |
#5 | $122.9M | 546 | N/A | N/A |
Fluidigm Corporation Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2001-11-13 | $34.0M | 3rd | Lehman Brothers | Article |
| 2002-11-14 | $Undisclosed | Lead Investor: Lilly | Article | |
| 2004-01-07 | $21.0M | Lead Investor: EDB I | Article | |
| 2006-06-28 | $Undisclosed | E | AllianceBernstein L.P | Article |
| 2007-01-09 | $37.0M | E | Wasatch Advisors Inc, Cross Creek Capital | Article |
| 2009-09-02 | $10.7M | Undisclosed | Article | |
| 2009-11-20 | $7.5M | Undisclosed | Alloy Ventures, EDB Investments | Article |
| 2012-08-17 | $52.2M | Undisclosed | Article | |
| 2012-08-22 | $60.0M | Undisclosed | Piper Jaffray & Co, Cowen and Company LLC | Article |
| 2014-01-30 | $175.0M | Undisclosed | Article | |
| 2017-08-14 | $30.0M | Undisclosed | Article |